Statins are associated with reduced use of steroids in inflammatory bowel disease: A retrospective cohort study

Inflammatory Bowel Diseases

Volumn 18, Issue 6, 2012, Pages 1048-1056

  Crockett, Seth D ^a   Hansen, Richard A ^b   Stürmer, Til ^c   Schectman, Robin ^d   Darter, Jane ^d   Sandler, Robert S ^a   Kappelman, Michael D ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina   (United States)

^c IL   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Crohn's disease; glucocorticoids; hydroxymethylglutaryl CoA reductase inhibitors; inflammatory bowel diseases; ulcerative colitis

Indexed keywords

ADALIMUMAB; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STEROID;

ABDOMINAL SURGERY; ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; HAZARD RATIO; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS;

AGED; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84860672665     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21822     Document Type: Article

References (36)

1. Herrinton LJ, Liu L, Lewis JD, et al. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol. 2008; 103: 1998-2006.
2. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007; 5: 1424-1429.
3. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007; 5: 1430-1438.
4. Ritchie JK, Powell-Tuck J, Lennard-Jones JE,. Clinical outcome of the first ten years of ulcerative colitis and proctitis. Lancet. 1978; 1: 1140-1143.
5. Reinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis. 2007; 13: 1135-1140.
6. Terzic J, Grivennikov S, Karin E, et al. Inflammation and colon cancer. Gastroenterology. 2010; 138: 2101-2114 e2105.
7. Card T, Hubbard R, Logan RF,. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology. 2003; 125: 1583-1590.
8. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
9. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476.
10. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005; 353: 362-368.
11. Stallmach A, Hagel S, Bruns T,. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010; 24: 167-182.
12. Cohen RD,. The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010; 7: 103-109.
13. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008; 135: 1907-1913.
14. Li M, Ong KL, Tse HF, et al. Utilization of lipid lowering medications among adults in the United States 1999-2006. Atherosclerosis. 2010; 208: 456-460.
15. Primatesta P, Poulter NR,. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 2000; 321: 1322-1325.
16. Lee JY, Kim JS, Kim JM, et al. Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol. 2007; 7: 241-248.
17. Grip O, Janciauskiene S,. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One. 2009; 4: e5263.
18. Grip O, Janciauskiene S, Lindgren S,. Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin. Inflamm Bowel Dis. 2004; 10: 193-200.
19. Suzuki S, Tajima T, Sassa S, et al. Preventive effect of fluvastatin on ulcerative colitis-associated carcinogenesis in mice. Anticancer Res. 2006; 26: 4223-4228.
20. Sasaki M, Bharwani S, Jordan P, et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J Pharmacol Exp Ther. 2003; 305: 78-85.
21. Higgins PD, Khan T, Mapili J, et al. Atorvastatin decreases Seo Index in patients with short duration of disease in ulcerative colitis: a randomized placebo-controlled clinical trial. Gastroenterology. 2006; 130: A120-A120.
22. Grip O, Janciauskiene S, Bredberg A,. Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. Br J Pharmacol. 2008; 155: 1085-1092.
23. Behm B, Pizarro T, Cominelli F,. Statin Therapy in Active Crohn's Disease. Am J Gastroenterol. 2009; 104: S482.
24. Ha C, Magowan S, Accortt NA, et al. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol. 2009; 104: 1445-1451.
25. Loftus EV, Jr., Delgado DJ, Friedman HS, et al. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol. 2008; 103: 1737-1745.
26. Motsko SP, Russmann S, Ming EE, et al. Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice. Pharmacoepidemiol Drug Saf. 2009; 18: 1214-1222.
27. Zhou F, Harpaz R, Jumaan AO, et al. Impact of varicella vaccination on health care utilization. JAMA. 2005; 294: 797-802.
28. Cohen FJ, Neslusan CA, Conklin JE, et al. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003; 26: 1847-1851.
29. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003; 158: 915-920.
30. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009; 15: 728-740.
31. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
32. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
33. Lewis JD, Aberra FN, Lichtenstein GR, et al. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology. 2004; 126: 665-673.
34. Robertson TA, Cooke CE, Wang J, et al. Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertension. Am J Manag Care. 2008; 14: 710-716.
35. LaFleur J, Thompson CJ, Joish VN, et al. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother. 2006; 40: 1274-1279.
36. Herrinton LJ, Liu L, Lafata JE, et al. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis. 2007; 13: 451-461.